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 Ho, Jessie. M.S. The University of Memphis. December, 2014. The Adequacy of 
Essential Fatty Acid in Patients with Phenylketonuria or Hyperphenylalaninemia: A 
Retrospective Study. Major Professor: Dr. Ruth Williams-Hooker 
Objective To investigate if patients diagnosed with phenylketonuria (PKU) or 
hyperphenylalaninemia (HPA) at the mid-south clinic had adequate essential fatty 
acid intakes. 
Design This study compared patients’ intakes of linoleic (LA) and alpha-linolenic 
fatty acids (ALA) with Adequate Intake (AI) within an appropriate age and gender 
group. Data were gathered from existing food record analyses from MetabolicPro 
between June 2010 and December 2013. Means and standard deviations for 
percentage of essential fatty acid intakes were determined. A paired t-test was used to 
test the hypothesis that the mean intake of LA and ALA were equal. T-tests were 
performed to examine whether the mean percentage of each fatty acid was equal to 
100%.  
Subjects Patients who were diagnosed with PKU or HPA, between 0- 58 years old, 
and had at least one 3-day food record analysis within the stated time frame (n=26). 
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Phenylketonuria (PKU) and hyperphenylalaninemia (HPA) are an inborn error of 
metabolism (IEM) that affects the use of certain amino acids in the body.1 These 
disorders are caused by mutations in genes coding a hepatic enzyme called 
phenylalanine hydroxylase (PAH) that converts an essential amino acid phenylalanine 
(Phe) to another amino acid tyrosine (Tyr).2 If left untreated, PKU or HPA patients 
would have elevated levels of Phe and low levels of Tyr in the blood.1 Toxicity of Phe 
can cause brain damage which can result in irreversible neurocognitive impairment.3 
Untreated PKU or HPA patients may also demonstrate psychiatric behaviors such as 
aggression and anxiety.4 
In the United States, it is estimated that PKU and HPA occur in one per 13,500 to 
19,000 births,1 and there were approximately 15,000 individuals diagnosed with the 
disorders from 1965 to 2010.5 Phenylketonuria and HPA are autosomal recessive 
disorders, meaning that the parents of a PKU or HPA patient must each carry at least a 
copy of the mutated gene for the corresponding enzymes.2 Carriers of the abnormal 
gene for the enzymes usually do not show signs or symptoms of PKU or HPA.2 The 
diagnostic differences between PKU and HPA are based on the presence and activity 
of PAH.1,6  
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Newborns have been screened for PKU and HPA since the 1960s in the United 
States.7 Newborn screening is necessary to identify PKU and HPA patients before 
permanent brain damage occurs. Once individuals are diagnosed with PKU or HPA, 
they have to follow a life-long diet that is low in Phe.1 It is important for PKU and 
HPA patients to maintain optimal Phe levels to support normal growth and 
development while receiving adequate nutrients.4 As Phe is present in almost all 
protein sources such as meat, fish, poultry, and dairy, the diet of PKU and HPA 
individuals strictly excludes protein-rich foods and other foods that are high in 
phenylalaine.1 Although PKU and HPA individuals are restricted in the amount of Phe 
they can eat, it is also necessary to obtain an adequate amount of the amino acid 
because Phe is an essential amino acid needed for muscle growth and repair and 
mental functions.4 Tyrosine is also an indispensable nutrient in PKU and HPA patients 
due to the impairment of the hepatic enzymes.5 In order to ensure normal 
development and maintenance, PKU and HPA patients are treated with medical 
formulas that contain many vitamins and minerals, and all essential amino acids but 
Phe.4 Therefore, individuals with PKU or HPA have a very restrictive diet and receive 
most of their protein from formulas and some from natural sources such as fruits and 




Due to the restrictive nature of the diet, PKU or HPA patients may be at risk of 
nutrient deficiencies.8 Studies have shown that individuals with PKU have a limited 
intake of certain polyunsaturated fatty acids (PUFAS).4,5 PUFAS can be at n-3 or n-6 
series.4 Examples of n-6 PUFAS include linoleic acids (LAs) and arachidonic acids 
(ARAs), and they are known as omega 6 fatty acids.9 Alpha-linolenic acids (ALAs) 
and docosahexaenoic acids (DHAs) are examples of n-3 PUFAS, and they can be 
referred as omega 3 fatty acids.9 Linoleic acids and ALAs are essential fatty acids 
because they can only be obtained from exogenous sources.10 Linoleic acids are the 
precursor of ARAs which are long-chain fatty acids11 while ALAs are the precursor of 
eicosapentaeonic acids (EPAs) and docosahexanoic acids (DHAs).12 Arachidonic 
acids are used by the body to synthesize eicosanoid and its derivatives.11 It has been 
found that PKU and HPA patients generally have sufficient intakes of LAs, and the 
conversion to ARAs usually meets the intake requirement for ARAs.10 On the other 
hand, studies have shown that the conversion of ALAs to EPAs and DHAs is low in 
the human body.10 Studies also suggested that PKU patients may have compromised 
ability to synthesize EPAs and DHAs.13,14 An adequate intake of omega-3 fatty acid 
has been linked to various health benefits including lower risk for certain cancers, and 




In view of the potential deficiency of LAs and ALAs, and their role in normal 
body functions and health benefits, it is necessary to access the dietary intake status of 
these two essential fatty acids in PKU and HPA patients. The purpose of this study 
was to investigate the adequacy of LA sand ALAs in patients diagnosed with PKU or 



















REVIEW OF LITERATURE 
 
Inborn Errors of Metabolism 
Inborn Errors of Metabolism are rare genetic disorders where the human body 
lacks specific enzymes that help metabolize nutrients. In 1908, Sir Archibald Garrod 
first described IEM as lifetime conditions that involved blocks in metabolic pathways, 
resulting in accumulation of precursors, and deficiency in products.16 There are more 
than 200 known metabolic disorders to date, and the majority of them are inherited 
through autosomal recessive traits, meaning both parents must carry at least one of the 
defective genes and pass it to the offspring.16 Symptoms of a recessive IEM will only 
be apparent if the individual has both defective genes, whereas the individual with 
only one mutated or absent gene usually does not show any symptoms. In the United 
States, about one out of every 1,000 newborns are diagnosed with IEM each year,16 
and PKU is among one of the most common IEM.  
Newborn Screening 
Newborn screening for PKU and HPA was first introduced in the United States 
in the 1960s. Before newborn screening, these disorders were generally diagnosed 
after developmental delays had been observed.7 Most newborns are now screened for 
6 
 
over 40 different disorders, and screening for PKU and HPA is practiced in all 50 
states.17 Screening is done by taking a few drops of blood from the newborn’s heel 
between 24 hours to seven days after birth, and the blood is sent to the laboratory for 
analysis.17 In some states, newborns are screened a second time two weeks after 
birth.18 Newborns whose Phe levels in blood exceed 10mg/dL will immediately be put 
on treatment for PKU and HPA, though a differential diagnosis is needed to confirm 
the condition.3 The primary newborn screening method used for PKU and HPA in the 
United States is performed by tandem mass spectrometry.6 From 1996 to 2005, over 
40 million newborns were screened and 3,173 of them were diagnosed with PKU.7 
Phenylketonuria 
Phenylketonuria is an IEM that affects the use of amino acid Phe in the body.1 
This disorder may result from defects in hepatic enzyme phenylalanine hydroxylase 
(PAH).28 The enzyme catalyzes the conversion of essential amino acid Phe to another 
amino acid Tyr.1 Phe may accumulate in the blood and other tissues if PKU patients 
are not treated, and prolonged elevated Phe levels could cause brain damage which 
can result in neurocognitive impairment such as mental retardation, delayed speech, 
and seizures.1 Musty body odor and eczema may result from excretion of excessive 
Phe and its metabolites.19 Phenylalanine hydroxylase deficiency occurs in a range of 
severity and the most severe type is classical PKU in which patients completely lack 
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PAH and therefore if they are untreated, their blood Phe levels tend to be greater than 
1,200 µmol/l. Hyperphenylalaninemia is less severe in which untreated patients 
typically have Phe levels higher than normal (60 µmol/l) but less than 1,200 µmol/l.1 
It is estimated that in the United States, PKU occurs in one per 13,500 to 19,000 
births while HPA occurs in 1 per 48,000 newborns.1 The incidence of PKU is higher 
in Caucasians and Native Americans, and lower in Blacks, Hispanics, and Asians.1  
Nutrition Management for PKU and HPA 
The treatment goals for PKU and HPA are to maintain Phe and Tyr within a 
normal range, support normal growth and development, maintain adequate nutrition 
status, and prevent neurocognitive abnormalities and physical manifestations such as 
musty body odor and osteopenia.3 The recommended daily Phe and Tyr intake for 
PKU and HPA patients varies with age and maternal status (Table 1).6 
Once individuals are diagnosed with PKU or HPA, they are on a lifelong diet 
that is low in Phe.18 The diet of PKU and HPA individuals strictly excludes protein-
rich foods as almost all of them contain high levels of Phe that cannot be tolerated by 
patients.1 Although PKU and HPA patients are restricted on Phe intake, it is necessary 
to obtain an adequate amount of this essential amino acid because Phe is necessary for 
muscle growth and repair and proper mental functions.4 Tyr is also an indispensable 
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amino acid in patients with PKU or HPA because of the body’s impaired ability to 
convert Phe to Tyr.5 It is crucial for PKU and HPA patients to maintain normal Tyr 
levels because the amino acid is involved in the synthesis of protein, thyroxine, 
catecholamines, and melanin.20 As natural protein intake is limited in individuals with 
PKU or HPA, most of the protein and energy requirements are met by Phe-free 
formulas fortified with Tyr.21 The rest of the nutrient and energy needs can be 
obtained from natural foods. Patients will PKU or HPA may need extra calories and 
nutrients from low-Phe foods such as fruits, non-starchy vegetables, and fats.21 In 
addition to formulas, products such as low-protein pasta and bread can be consumed 
in moderate amounts to add variety to the diet of PKU and HPA patients.20 The 
outcomes of nutritional management for PKU and HPA are monitored through 
measurement of Phe and Tyr levels in blood, along with the analysis of nutritional 
intake and status.1 Recent recommendations for daily intake of Phe and Tyr for PKU 
and HPA patients were published in 2014 by the American College of Medical 
Genetics and Genomics, and the recommended intake varies with age and maternal 






Table 1. Recommended Daily Phenylalanine and Tyrosine Intake for 
Patients with Phenylketonuria or Hyperphenylalaninemia6  
   
 Age                           Phe (mg/day)    Tyr (mg/day) 
0<3 months 130-430 1,100-1,300 
3-6 months 135-400 1,400-2,100 
6-9 months 145-370 2,500-3,000 
9<12 months 135-330 2,500-3,000 
1-4 yrs old 200- 320 2,800-3,500 
4 yrs to adult 200-1,100 4,000-6,000 
   
Pregnancy/lactation   
Trimester 1 265-770 6,000-7,600 
Trimester 2 400-1,650 6,000-7,600 
Trimester 3 700-2,275 6,000-7,600 
Lactation 700-2,275 6,000-7,600 
 
Other Treatments for PKU and HPA 
Tetrahydrobiopterin   
In addition to a permanent Phe-restricted diet, some individuals diagnosed with 
PKU or HPA are treated with tetrahydrobiopterin (BH4) which is a cofactor that 
facilitates the activity of residual PAH to convert Phe to Tyr.21 As a result, Phe levels 
in blood decrease while Phe tolerance increases, allowing individuals to have a less 
restrictive diet. Trefz F. K. et al.22 studied the long-term effects of BH4 in eight 
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children with mild PKU over a total of 18 treatment years. Results indicated that the 
children maintained low blood Phe levels and had increased Phe tolerance, with no 
major side effects observed during treatment. Another study done in Germany 
examined the long-term treatment of BH4 on a larger PKU population.
23 In the study, 
all 24 patients who were sensitive to BH4 showed improvement on daily Phe tolerance 
from 452 ± 201 mg/day to 1593 ± 647 mg/day. Although studies have showed 
promising results from BH4 supplementation,
22,23 only a number of PKU patients are 
responsive to the treatment. Individuals with mild or moderate PKU are more likely to 
show positive outcomes from BH4 while only 10% of individuals with classical PKU 
respond to the treatment.19 The responsiveness to BH4 has been linked to the types of 
mutation of PAH.24 It is worth noting that even though BH4 supplementation may help 
with Phe control, only a minority of PKU patients are able to stop the low-Phe diet 
including the formula.20,24 
Large Neutral Amino Acids 
Large neutral amino acids (LNAAs) including Tyr, tryptophan, threonine, 
methionine, valine, isoleucine, leucine, and histidine may be used as supplements in 
PKU or HPA patients who have low compliance to the diet.5 Phenylalanine competes 
with LNAAs for carrier proteins that transport amino acids across the intestine to the 
blood and the blood-brain barrier to the brain.20 Therefore, supplementation of 
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LNAAs may help reduce the influx of Phe in the blood and the brain, which prevents 
Phe toxicity.20 It is also believed that LNAAs may lead to an increase in brain 
neurotransmitter and amino acid levels.24 Further studies are needed to fully 
investigate the long-term effects and efficacy of LNAAs on PKU or HPA 
patients.5,19,20,24   
Glycomacropeptide 
Glycomacropeptide (GMP) is a natural, purified whey protein derived from diary 
sources that is low in Phe, Tyr, and tryptophan.24 Therefore, GMP provides an 
alternative protein source for individuals with PKU or HPA. A study was done on the 
safety, acceptability, and efficacy of GMP in the PKU diet. Van Calcar et al.25 
compared the acceptability and blood amino acid profiles in PKU patients who had 
had both the classic PKU diet with synthetic amino acids and the diet supplemented 
with GMP. Ten out of eleven subjects preferred the diet with GMP products, and their 
fasting and postprandial blood Phe levels were higher with the classic diet than with 
the GMP diet, suggesting the GMP diet maintained more stable plasma Phe 
concentrations.25 
Essential Fatty Acids 
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 The human body lacks the ability to synthesize essential fatty acids, thus, they 
need to be ingested.10 There are two known essential fatty acids for humans: linoleic 
fatty acids (LA/ omega-6 fatty acids) and alpha-linolenic fatty acids (ALA/ omega-3 
fatty acids). Linoleic acids and ALA are also known as polyunsaturated fatty acids 
(PUFAs) as they contain more than one double bond. The main sources for LA and 
ALA are plant-based: LA is abundant in liquid vegetable oils, nuts, and seeds, 
whereas ALA can be found in soybean oil, canola oil, and walnuts.11 Essential fatty 
acids play an important role in maintaining a good health status. For example, an 
optimal consumption of LA has been shown to decrease total and low-density 
lipoprotein cholesterol which is often referred as the “bad” cholesterol.11  
Although humans are not able to synthesize the essential fatty acids, LA and ALA 
can be metabolically converted into various long-chain PUFAs (LCPUFAs). Linoleic 
acid is the precursor of a 20-carbon long fatty acid called arachidonic acid (ARA),11 
and ALA can be synthesized into eicosapentaeonic acid (EPA) and docosahexanoic 
acid (DHA).12 Arachidonic acid is the primary substrate for the synthesis of 
eicosanoid and its derivatives such as prostaglandins, thromboxanes, and 
leukotrienes.11 ARA is the main component of the inositol glycerophospholipids as 
well.10 It is generally agreed that the intake requirement for ARA can be met by the 
synthesis from dietary LA.10 However, studies have consistently shown that only a 
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small proportion of dietary ALA is converted to EPA and DHA in the human body 
and the conversion rates vary by genders.12,26 Males seem to have <4% of conversion 
rate from ALA to DHA while females have up to 9% of dietary ALA be converted 
into DHA.12  
Extensive research studies have been done to investigate the effects of omega-3 
fatty acids on health. It is widely agreed that omega-3 fatty acids are pertinent to 
visual, cognitive, and cardiovascular development and functions. Some studies have 
demonstrated the association between omega-3 fatty acids and other health benefits. A 
review of literature by Campoy et al.15 suggested omega-3 LCPUFA supplementation 
in pregnant women would increase the infant’s birth weight, birth length, and head 
circumference. There was also an increase in gestation length to about 2.5 days. Azrad 
et al.9 studied the correlation of PUFAs supplementation and certain cancers in a 
meta-analysis. They found conflicting results on intake of PUFAs and risk for 
cancers. One of the studies they looked at showed a positive relationship with DHA 
intake and risk for pancreatic cancer. Another study found that EPA significantly 
negatively associated with fatal prostate cancer.  
The Dietary Reference Report (DRI) report on macronutrients provided an 
Adequate Intake (AI) for LA and ALA (Table 2, Table 3).27 The position of the 
Academy of Nutrition and Dietetics (formerly known as the American Dietetic 
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Association) and Dietitians of Canada emphasizes that “AI are the observed median 
intakes of n-6 and n-3 fatty acids for the US population, and should not be confused 
with the Recommended Dietary Allowance (RDA) or with those intakes of fatty acids 
that confer the lowest risk of disease”.11 Adequate Intake are observed estimates of 
daily intake by a group or groups of healthy people and are only established when an 
RDA cannot be determined.28 Although there are no set recommendations for EPA or 
DHA, it is recommended by US Dietary Guidelines Advisory Committee and the 
American Heart Association that two servings of fatty fish per week provide about 














Table 2. Adequate Intake for Linoleic Fatty Acids27   
 
Age                                  AI (g/d) 
0 - 6 mo 4.4 
7 - 12 mo 4.6 
1 - 3 y 7 
4 - 8 y 10 
Males  
9 - 13 y 12 
14 - 18 y 16 
19 - 30 y 17 
31 - 50 y 17 
50 - 70 y 14 
> 70 y 14 
Females  
9 - 13 y 10 
14 - 18 y 11 
19 - 30 y 12 
31 - 50 y 12 
50 - 70 y 11 
> 70 y 11 
Pregnancy  
< 18 y 13 
19 - 30 y 13 
31 - 50 y 13 
Lactation  
< 18 y 13 
19 - 30 y 13 







Table 3. Adequate Intake for Alpha-Linolenic Fatty Acids27  
 
Age AI (g/d) 
0 - 6 mo 0.5 
7 - 12 mo 0.5 
1 - 3 y 0.7 
4 - 8 y 0.9 
Males  
9 - 13 y 1.2 
14 - 18 y 1.6 
19 - 30 y 1.6 
31 - 50 y 1.6 
50 - 70 y 1.6 
> 70 y 1.6 
Females  
9 - 13 y 1.0 
14 - 18 y 1.0 
19 - 30 y 1.1 
31 - 50 y 1.1 
50 - 70 y 1.1 
> 70 y 1.1 
Pregnancy   
< 18 y 1.4 
19 - 30 y 1.4 
31 - 50 y 1.4 
Lactation  
< 18 y 1.3 
19 - 30 y 1.3 





Essential Fatty Acid Status in PKU and HPA Patients 
 It has been documented that due to the restrictive nature of the diet, PKU or HPA 
patients are at risk for vitamin and mineral deficiencies such as iron, calcium, vitamin 
D, and vitamin B12.8 In addition to micronutrients, studies have shown that 
individuals with PKU or HPA have a limited intake of certain LCPUFAS.4,13 Van Gool 
et al. found that subjects with PKU consumed more LA and less ALA than controls 
who were on a regular diet, and blood test results were consistent with the differences 
in fatty acid intake among two groups.29 In a study on the lipid profiles of 24 PKU 
patients, when compared to normal individuals, PKU patients had lower plasma ARA 
and DHA levels.13 The study also suggested that the endogenous synthesis of DHA 
and ARA might be impaired in PKU patients because their plasma concentrations of 
ALA and LA were similar to that of the control group.13 A literature review of papers 
suspected there may be an inhibitory effect of Phe metabolites such as phenylpyruvate 
and phenyllactate on DHA and ARA synthesis in the body.14  
Summary 
 Phenylketonuria and HPA are life-long conditions that require high compliance 
to a low-Phe diet and lifelong consumption of medical formulas. The highly 
restrictive diet may lead to deficiency in micro- and macronutrients. In this study, the 
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intake of LA and ALA in PKU and HPA patients is of particular interest because an 

























 This retrospective study investigated the intake of essential fatty acids- linoleic 
acids (LA) and alpha-linoleic acids (ALA) in patients with PKU or HPA at the mid-
south clinic.  
Population 
 Qualified participants had a diagnosis of PKU or HPA and had completed at least 
one 3-day food record, analyzed by MetabolicPro between June 2010 and December 
2013, starting from the launching of the tool until the time when data collection was 
initiated.30 Twenty-six patients met the criteria and their food record analyses were 
used for the study. 
Instrument  
 The 3-day food records were analyzed by an online tool called MetabolicPro 
which is designed specifically for metabolic dietitians or nutritionists to examine the 
diets of patients with metabolic disorders.30 This tool is operated by Genetic 
Metabolic Dietitians International. The nutrition facts in MetabolicPro are based on 
the nutrient database of the United States Department of Agriculture and other 
resources such as Amino Acid Analyzer. This web-based tool analyzes more than 50 
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nutrients including LA and ALA.30  
Procedures 
 Patients with PKU or HPA visited the mid-south clinic regularly to meet with the 
metabolic dietitian. They were asked to provide a 3-day food record with the name 
and amount of food and drink consumed during the 3 days prior to the visit. The 
dietitian or nutrition trainee then entered the intake data on MetabolicPro. When food 
or drink items were not found on MetabolicPro, the dietitian or nutrition trainee chose 
the most similar items possible. The nutrient analysis of the 3-day food record was 
compared with the Dietary Reference Intake or Adequate Intake lied within respective 
gender and age group. In this study, data were collected retrospectively from patients’ 
past food record analyses. Patients’ intakes of LA and ALA were compared with the 
AI of the two essential fatty acids within appropriate gender and age group (Table 2 & 
3). If there was more than one 3-day food record analysis from the patient, results 
were averaged for analysis. If the patient had more than ten 3-day food record 
analyses within the stated time frame, only the most recent ten 3-day food record 
analyses were used.  
Analysis 
 Research results were analyzed using Microsoft Excel Statistics (Microsoft, 
2010). Descriptive analysis was used to determine means and standard deviations for 
21 
 
percentage of essential fatty acid intake. A paired t-test was used to test the hypothesis 
that the mean of LA intake and that of ALA acid were equal. In addition, individual t-





















 There were a total of 26 patients in the study, including 11 females and 15 males 
with an age range from 0 to 58 years old. All individuals were diagnosed with either 
HPA or PKU. They completed at least one 3-day food record between June 2010 and 
December 2013, and the dietitian or nutrition trainee evaluated the food record using 
an online nutrient analyzer called MetabolicPro.  
Essential Fatty Acid Intakes 
    By comparing patients’ dietary intake of essential fatty acids to AI, none of them 
met the requirement for LA and only two patients reached the AI for ALA (Table 4). 
The average percentage of intake of LA was 32% (SD=0.049) while that of ALA was 
48% (SD=0.091) (Table 5). It should be noted that this estimate of the standard 
deviations does not take into consideration the fact that measurements made on the 
same individual at different times are likely to be correlated. A more sophisticated 
estimate of the standard deviations that takes into consideration the fact that these 
measurements may be correlated as well as the fact that there were different numbers 
of measurements for each individual was computed and found to be slightly more 
conservative than the standard error of the mean. 
23 
 
    Null hypotheses that the mean percentage of LA intake was equal to 100% and 
mean percentage of ALA intake was equal to 100% were tested using a t-test. Both 
null hypotheses were rejected with a very small p-value (close to zero) with both the 
standard error of the mean and the more sophisticated estimate. For this reason and 
for ease of reproduction, the more traditional standard error of the mean is reported 
and used to test the hypotheses (Table 6). A paired t-test was used to test whether the 
mean percentage of LA was the same as the mean percentage of ALA. The p-value 
for this test was 0.062 suggesting that the mean percentages are likely to be different 












Table 4. Average Percentage of Essential Fatty Acid Intake Compared to 
Adequate Intake 
 
   
Subjects Linoleic Fatty Acid Intake α-Linolenic Fatty Acid Intake  
1 13% 17%  
2 26% 57%  
3 1% 16%  
4 26% 81%  
5 34% 35%  
6 10% 10%  
7 21% 25%  
8 14% 24%  
9 42% 44%  
10 27% 30%  
11 11% 13%  
12 15% 23%  
13 90% 42%  
14 73% 53%  
15 50% 66%  
16 30% 37%  
17 49% 233%  
18 32% 36%  
19 10% 14%  
20 15% 12%  
21 98% 88%  
22 26% 29%  
23 4% 10%  
24 42% 107%  
25 54% 70%  






Table 5. Mean and Standard Deviation for Percentage of Essential Fatty Acid Intake 
 
 x̅ (SD)        
Linoleic Fatty Acid Intake                 32% (.049)     
α-Linolenic Fatty Acid Intake               48% (.091)        
 
Table 6. Paired T-test Comparing the Mean of Two Essential Fatty Acids 
 
  t df p value (2-tailed) 
x̅ of Linoleic Fatty Acid Intake vs.  
x̅ of α-Linolenic Fatty Acid Intake 


















Individuals with PKU have faced challenges meeting nutritional needs due to 
their highly restrictive diet. Micronutrient deficiencies such as vitamin B12, selenium, 
iron, and zinc have been reported in children and adults diagnosed with PKU or 
HPA.8 There have also been numerous studies that demonstrated that in comparison 
with regular counterparts, PKU patients have lower concentrations of essential fatty 
acids in the body. 4,13,14,29    
 The purpose of this study was to investigate whether or not PKU or HPA patients 
seen at the mid-south clinic met the intake requirement for essential fatty acids, with 
the attempt to contribute to existing knowledge. Data were collected from past food 
records of 26 patients (0- 58 years of age) and results showed that the majority of 
patients did not reach the Adequate Intake of both LA and ALA (Table 4). The 
findings were surprising because the subjects’ average intake of ALA was higher than 
that of LA (Table 5), as opposed to the general belief that the diet for PKU and HPA 
consists of disproportionately high amounts of LA.31   
 There are multiple factors that might contribute to the suboptimal intake of 
essential fatty acids. In addition to Phe-free formulas, the diet of a PKU or HPA 
patient after infancy is composed of mostly vegetables and fruits. Sources of LA and 
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ALA are mainly plant-based and foods such as nuts, seeds and fatty fish are rich in 
essential fatty acids and LCPUFAs, but are limited in a PKU or HPA diet because 
they contain high amounts of Phe. Modified low-protein foods such as meat 
alternatives and imitation dairy products have been developed to provide dietary 
options for persons with amino acid metabolic disorders. Although a number of 
patients consumed modified low-protein foods according to their food records, these 
food products are generally not supplemented with LA, ALA, or LCPUFAs, and thus, 
consuming these low-protein products was not a great help in meeting their essential 
fatty acids needs. Medical formulas are the foundation of the PKU diet as they are 
created to meet the nutrient needs of the specific population. The commonly used 
formulas among PKU and HPA patients at the mid-south clinic are supplemented with 
LA and ALA, which include Periflex Infant and Advanced, PhenylAde Essential 
Drink Mix, and Phenx-1 and -2. 32,33 Therefore, the author suspects that the 
suboptimal essential fatty acid intake might due to poor compliance to drinking these 
formulas as compliance issues are often observed in individuals with PKU. 20,34 
 The limitations of this study are multifactorial. First, the sample size was small 
(n=26), which might skew the results by extremely high or low intake values. Second, 
since data were collected from patients diagnosed with either PKU or HPA and then 
analyzed as a whole, the results are not completely indicative of the intake of patients 
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from one specific condition, especially since HPA patients at the mid-south clinic are 
prescribed a more liberal diet. Third, nutrition data of some food items were missing 
on MetabolicPro, which resulted in a less accurate representation of patients’ nutrient 
intakes. In addition, as the 3-day food records were self-reported, human biases were 
inevitable from under- or over-estimating intakes. Lastly, food record analyses were 
done by different personnel over time and this analysis approach therefore, might 
have caused differences in making estimates when certain food items could not be 
found on MetabolicPro.  
Conclusions 
 In conclusion, patients with PKU or HPA seen at the mid-south clinic did not 
meet the dietary requirements for essential fatty acids. When conducting similar 
studies in the future, data analysis can be done by taking into account the effects of 
genders, variants of PKU, ages, and types of formula consumed on differences in 
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